|Dr. Ching-Leou Teng Ph.D.||Chairman & Chief Pharmaceutical Officer||N/A||N/A||N/A|
|Mr. Ko-Chung Lin||Founder, CEO & Chief Strategy Officer||N/A||N/A||N/A|
|Mr. Chan-Kou Hwang||Pres, GM & Director||N/A||N/A||N/A|
|Ms. Snow Chang||Accounting Mang. & Sr. Mang. of Fin.||N/A||N/A||N/A|
|Dr. Albert Qin||Chief Medical Officer||N/A||N/A||N/A|
|Narihisa Miyachi||Head of Japan Medical Affairs||N/A||N/A||N/A|
|Mr. Yen-Tung Luan||Chief Operating Officer of Taichung Plant||N/A||N/A||N/A|
|Dr. Raymond W. Urbanski||Head of Clinical Devel. & Medical Affairs for U.S. Subsidiary||N/A||N/A||1959|
|Wu Kuo-Hsiung||Chief of Taichung Plant||N/A||N/A||N/A|
PharmaEssentia Corporation engages in the research, development, production, and sale of therapeutic products for the treatment of human diseases. Its products include ropeginterferon alfa-2b that is used for the treatment of polycythemia vera, essential thrombocythemia, and hepatitis B and C; and Anti-PD-1 antibody for the treatment of cancer. The company also licensed to develop Oraxol for the treatment of breast, advanced gastric, and esophageal cancer; KX01 for the treatment of psoriasis and actinic keratosis. It also focuses on the drug research and development programs in the areas of hematology, infectious disease, oncology, and dermatology. The company has a research collaboration agreement with Axis Therapeutics Limite for the development of T Cell Receptor-T therapy based on the T cell receptor affinity enhancing specific T cell therapy technology platform. PharmaEssentia Corporation was founded in 2003 and is headquartered in Taipei, Taiwan.
PharmaEssentia Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.